-19.5%
STM vs MRNA
-27.3%
+7.7%
-66.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -10.7% | -2.2% | -8.5% | -10.5% |
| 7D | -16.3% | -12.7% | -3.6% | -15.3% |
| 30D | -17.5% | -20.7% | +3.1% | -16.0% |
| 3M | -21.5% | +46.3% | -67.8% | -24.5% |
| 6M | -39.6% | +305.2% | -344.8% | -53.7% |
| YTD | +51.6% | +561.2% | -509.6% | +0.8% |
| 1Y | +86.2% | +772.1% | -685.9% | +14.8% |
| 3Y | -12.9% | +147.0% | -159.8% | -33.4% |
| All | -19.5% | -27.3% | +7.7% | -32.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling